- 362 Downloads
The World Tourism Organization estimated the number of international tourist arrivals to be 1.2 billion in 2016, an increase of 46 million over the previous year, a figure that has been rising constantly for 7 consecutive years. In this context, a long list of vaccines are dispensed and administered in travel clinics around the world. There are two main steps in immunizing travelers, namely, to update routine vaccinations and, second, to provide travel-specific immunization. For the first step, knowledge of a patient’s previous immunizations and personal medical history is necessary. For the second step, considerably more issues must be covered, including obtaining information about the patient’s projected itinerary, mode of travel, planned living conditions during the stay, and purpose of travel. This review focuses on three major and common travel vaccines, namely, yellow fever, dengue, and rabies. It should be remembered that vaccines exist both to protect the visited populations and the travelers, plus those the travelers come in contact with on their return from endemic areas. Travel should be used as a good opportunity to update routine vaccines.
KeywordsTravel Vaccine Dengue Rabies Yellow fever Travelers
- 1.World Tourism Organization (UNWTO). UNWTO Annual Report 2016. UNWTO, Madrid, Spain. 2017. https://www.e-unwto.org/doi/pdf/10.18111/9789284418725. Accessed 29 June 2018.
- 3.World Health Organization. WHO global yellow fever data base. http://apps.who.int/globalatlas/default.asp. Accessed 30 June 2018. (Latest data for Yellow Fever from 2005).
- 4.World Health Organization. International Health Regulations. 3rd ed. 2005. http://www.who.int/ihr/publications/9789241580496/en/. Accessed 30 June 2018.
- 5.Meeting of the Strategic Advisory Group of Experts on immunization, April 2013—conclusions and recommendations. Wkly Epidemiol Rec. 2013;88(20):201–6.Google Scholar
- 6.Vaccines and vaccination against yellow fever. WHO position paper—June 2013. Wkly Epidemiol Rec. 2013;88(27):269–83.Google Scholar
- 7.Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): summary report, February 26, 2015. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html. Accessed 30 June 2018.
- 9.Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Tropical Med Int Health. 1999;4(12):867–71.CrossRefGoogle Scholar
- 11.Ahuka-Mundeke S, Casey RM, Harris JB, Dixon MG, Nsele PM, Kizito GM, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak—preliminary report. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1710430
- 12.Soentjens P, Andries P, Aerssens A, Tsoumanis A, Ravinetto R, Heuninckx W, et al. Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy513
- 15.World Health Organization. Zero by 30: the global strategic plan to prevent human deaths from dog-transmitted rabies by 2030. 2017. http://www.who.int/rabies/Executive_summary_draft_V3_wlogo.pdf?ua=1. Accessed 1 July 2018.
- 16.Jonker EFF, Visser LG. Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study. J Travel Med. 2017;24(5).Google Scholar
- 17.World Health Organization. Rabies vaccines: WHO position paper—April 2018. Weekly Epidemiological Record No. 16, 2018, 93, 201–20. Weekly Epidemiological Record 2018;93(16):201–20. http://www.who.int/rabies/resources/who_wer9316/en/. Accessed 1 July 2018.
- 23.Saez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal AC, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis. 2018;18(2):162–70.CrossRefGoogle Scholar